Drugs / ampicillin/sulbactam
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT07563933 Comparator | May → Oct 2026 expected | — | Ministry of Health and Population, Egypt | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ampicillin/sulbactam | “Participants randomized to the short-course arm will receive intravenous ampicillin/sulbactam (dosage according to hospital formulary and weight-based guidelines) for a total...” NCT07563933 ↗ |
| Route | Intravenous | “receive intravenous ampicillin/sulbactam” NCT07563933 ↗ |